LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

Strona główna・Stock List・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Closed

SectorHealthcare

18.3 -3.02

Buy Sell

Overview

Share price change

24h

Current

Min

18.14

Max

18.87

Key metrics
By Trading Economics
Income	-607K -51M
Sales	-28M 100M
EPS	-0.46
Profit margin	-51.215
Employees	1,784
EBITDA	4.1M -44M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+81.71% upside

Dividends
By Dow Jones
Next Earnings	6 sie 2026

Market Stats
By TradingEconomics
Market Cap	-294M 2.1B
Previous open	21.32
Previous close	18.3

News Sentiment

By Acuity

45%

55%

152 / 345 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

28.13 / 31.12 Support & Resistance

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 maj 2026, 20:36 UTC

Acquisitions, Mergers, Takeovers

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 maj 2026, 23:47 UTC

Market Talk

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 maj 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 maj 2026, 23:28 UTC

Market Talk

Earnings

Global Forex and Fixed Income Roundup: Market Talk

19 maj 2026, 23:28 UTC

Market Talk

Earnings

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 maj 2026, 23:10 UTC

Market Talk

Global Equities Roundup: Market Talk

19 maj 2026, 23:10 UTC

Market Talk

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 maj 2026, 22:02 UTC

Earnings

ZTO Express (Cayman): Di Xu to Resign From Board

19 maj 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 maj 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 maj 2026, 22:00 UTC

Earnings

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 maj 2026, 21:37 UTC

Earnings

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 maj 2026, 21:31 UTC

Acquisitions, Mergers, Takeovers

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 maj 2026, 21:01 UTC

Earnings

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 maj 2026, 20:58 UTC

Earnings

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 maj 2026, 20:46 UTC

Hot Stocks

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 maj 2026, 20:43 UTC

Market Talk

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 maj 2026, 20:34 UTC

Earnings

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 maj 2026, 20:32 UTC

Earnings

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 maj 2026, 20:32 UTC

Earnings

James Hardie Industries 4Q EPS 5c >JHX

19 maj 2026, 20:32 UTC

Earnings

James Hardie Industries 4Q Sales $1.4B >JHX

19 maj 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Analog Devices to Buy Empower Semiconductor for $1.5B

19 maj 2026, 20:18 UTC

Market Talk

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 maj 2026, 20:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 maj 2026, 20:13 UTC

Market Talk

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 maj 2026, 20:03 UTC

Acquisitions, Mergers, Takeovers

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 maj 2026, 20:03 UTC

Acquisitions, Mergers, Takeovers

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 maj 2026, 20:02 UTC

Acquisitions, Mergers, Takeovers

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 maj 2026, 20:02 UTC

Acquisitions, Mergers, Takeovers

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 maj 2026, 19:23 UTC

Market Talk

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

81.71% upside

12 Months Forecast

Average 34.27 USD 81.71%

High 44 USD

Low 21.8 USD

Based on 4 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Zai Lab Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

28.13 / 31.12Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

152 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.